See more : Smith & Nephew plc (SN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Myomo, Inc. (MYO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myomo, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Tern Plc (TERNF) Income Statement Analysis – Financial Results
- ACS, Actividades de Construcción y Servicios, S.A. (ACS.MC) Income Statement Analysis – Financial Results
- 4iG Nyrt. (4IG.BD) Income Statement Analysis – Financial Results
- Elsight Limited (ELSLF) Income Statement Analysis – Financial Results
- Molten Metals Corp (MOLT.CN) Income Statement Analysis – Financial Results
Myomo, Inc. (MYO)
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.10M | 689.67K | 913.25K |
| Cost of Revenue | 6.06M | 5.30M | 3.54M | 2.60M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| Gross Profit | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Profit Ratio | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.20% | 67.59% | 74.42% | 64.56% | 76.83% |
| Research & Development | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| General & Administrative | 16.02M | 14.37M | 14.44M | 12.98M | 11.25M | 10.41M | 5.85M | 2.93M | 3.10M | 2.85M |
| Selling & Marketing | 3.22M | 4.07M | 3.59M | 841.30K | 301.70K | 136.30K | 31.00K | 41.60K | 119.70K | 14.30K |
| SG&A | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| Other Expenses | 0.00 | -1.10K | -16.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.60M | 4.10M | 3.98M | 3.44M |
| Cost & Expenses | 27.47M | 26.23M | 24.12M | 18.09M | 14.63M | 12.97M | 8.11M | 4.38M | 4.22M | 3.65M |
| Interest Income | 410.27K | 88.73K | 1.61K | 474.71K | 112.49K | 0.00 | 0.00 | 0.00 | 196.06K | 178.86K |
| Interest Expense | 0.00 | 88.73K | 15.34K | 474.71K | 113.63K | 358.92K | 358.92K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.42K | 7.73K | 5.31K | 6.16K |
| EBITDA | -7.71M | -10.13M | -9.93M | -11.24M | -10.70M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Ratio | -40.09% | -65.12% | -71.68% | -137.06% | -283.88% | -429.40% | -86.36% | -296.14% | -511.58% | -299.50% |
| Operating Income | -8.23M | -10.67M | -10.27M | -10.50M | -10.80M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Income Ratio | -42.78% | -68.61% | -74.10% | -138.50% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Total Other Income/Expenses | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Income Before Tax | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.10M | -3.62M | -3.73M | -2.92M |
| Income Before Tax Ratio | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax Expense | 156.00K | 69.94K | 88.93K | 474.71K | -81.99K | -247.95K | 5.57M | 342.02K | 752.61K | 607.62K |
| Net Income | -8.15M | -10.72M | -10.37M | -12.04M | -10.63M | -10.32M | -12.10M | -3.62M | -4.48M | -3.53M |
| Net Income Ratio | -42.34% | -68.92% | -74.86% | -158.75% | -277.01% | -422.11% | -776.04% | -327.84% | -649.90% | -386.29% |
| EPS | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Diluted | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| Weighted Avg Shares Out | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Weighted Avg Shares Out (Dil) | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December...
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December...
Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and...
Independent Research with Myomo's MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company's MyoPro myoelectric...
Myomo Provides Update on MyoPro® Insurance Reimbursement
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a...
Myomo Announces MyoPro® 2+
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the availability of MyoPro 2+, an enhanced version of its...
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the entry into an amended and restated joint venture agreement...
Myomo: Following The Same Path With Less Cash
Myomo has a great deal of similarities in business strategy to its technological & industry peers in terms of markets, joint ventures, and insurance reimbursements. However, its cash position is much weaker, and will quite likely need to raise additional...
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2021 Results - Earnings Call Transcript
Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports